Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: Accurate detection of CA19-9 levels in pancreatic cancer
dc.contributor.author | Grote, Tobias | en_US |
dc.contributor.author | Siwak, Doris R. | en_US |
dc.contributor.author | Fritsche, Herbert A. | en_US |
dc.contributor.author | Joy, Corwin | en_US |
dc.contributor.author | Mills, Gordon B. | en_US |
dc.contributor.author | Simeone, Diane M. | en_US |
dc.contributor.author | Whitcomb, David C. | en_US |
dc.contributor.author | Logsdon, Craig D. | en_US |
dc.date.accessioned | 2008-08-27T20:04:26Z | |
dc.date.available | 2009-10-02T17:27:37Z | en_US |
dc.date.issued | 2008-08 | en_US |
dc.identifier.citation | Grote, Tobias; Siwak, Doris R.; Fritsche, Herbert A.; Joy, Corwin; Mills, Gordon B.; Simeone, Diane; Whitcomb, David C.; Logsdon, Craig D. (2008). "Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: Accurate detection of CA19-9 levels in pancreatic cancer." PROTEOMICS 8(15): 3051-3060. <http://hdl.handle.net/2027.42/60898> | en_US |
dc.identifier.issn | 1615-9853 | en_US |
dc.identifier.issn | 1615-9861 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/60898 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=18615426&dopt=citation | en_US |
dc.description.abstract | The current study analyzed reverse phase protein arrays (RPPA) as a means to experimentally validate biomarkers in blood samples. One microliter samples of sera ( n 14= 1471), and plasma ( n 14= 1478) were serially diluted and printed on NC-coated slides. CA19-9 levels from RPPA results were compared with identical patient samples as measured by ELISA. There was a strong correlation between RPPA and ELISA ( r 14= 140.87) as determined by scatter plots. Sample reproducibility of CA19-9 levels was excellent (interslide correlation r 14= 140.88; intraslide correlation r 14= 140.83). The ability of RPPA to accurately distinguish CA19-9 levels between cancer and noncancer samples were determined using receiver operating characteristic curves and compared with ELISA. The AUC for RPPA and ELISA was comparable (0.87 and 0.86, respectively). When the mean CA19-9 levels of normal samples was used as a cutoff for RPPA and compared with the standard clinical ELISA cutoff, comparable specificities (71% for both) were observed. Notably, RPPA samples normalized to albumin showed increased sensitivity compared to ELISA (90% vs . 75%). As RPPA is a high-throughput method that shows results comparable to that of ELISA, we propose that RPPA is a viable technique for rapid experimental screening and validation of candidate biomarkers in blood samples. | en_US |
dc.format.extent | 427638 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | WILEY-VCH Verlag | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.title | Validation of reverse phase protein array for practical screening of potential biomarkers in serum and plasma: Accurate detection of CA19-9 levels in pancreatic cancer | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Molecular, Cellular and Developmental Biology | en_US |
dc.subject.hlbsecondlevel | Biological Chemistry | en_US |
dc.subject.hlbsecondlevel | Chemical Engineering | en_US |
dc.subject.hlbsecondlevel | Chemistry | en_US |
dc.subject.hlbsecondlevel | Materials Science and Engineering | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Engineering | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Surgery, University of Michigan, Ann Arbor, MI, USA | en_US |
dc.contributor.affiliationother | Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA ; Both authors contributed equally to this study. | en_US |
dc.contributor.affiliationother | Department of Systems Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA | en_US |
dc.contributor.affiliationother | Department of Laboratory Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA | en_US |
dc.contributor.affiliationother | Departments of Bioinformatics and Computational Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA | en_US |
dc.contributor.affiliationother | Department of Systems Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA | en_US |
dc.contributor.affiliationother | Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA | en_US |
dc.contributor.affiliationother | Department of Cancer Biology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA ; Department of GI Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA ; 1515 Holcombe, Unit 953, Houston, TX 77030-4009, USA Fax: +1-713-563-8986 | en_US |
dc.identifier.pmid | 18615426 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/60898/1/3051_ftp.pdf | |
dc.identifier.doi | http://dx.doi.org/10.1002/pmic.200700951 | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.